interferon alfa-2b | Grippferon nasal drops 10,000 IU / ml, 10 ml

Release form

Drops for intranasal use.

Packing

Bottle of 10 ml.

Pharmacological action

Grippferon is a broad-spectrum drug (rhino, corona, adenoviruses, influenza, parainfluenza, etc.). With the intranasal route of administration, it provides prolonged contact with the mucous membrane of the nasal cavity, acting on the site of the primary introduction and reproduction of respiratory viruses. The activity of 1 vial of Grippferon is equal to the activity of 100 ampoules of human leukocyte interferon.

Grippferon does not develop addiction and resistance. The drug, as a rule, does not require additional symptomatic treatment (aspirin, panadol, sulfonamides, vasoconstrictor drops for the nose). A carefully selected composition, thanks to the additional absorbent and drying effect, allows you to enhance the therapeutic effect of interferon itself.

From the first hours of taking the drug, the removal of the main symptoms of the disease (runny nose, fever, headache, hyperemia of the oropharynx, etc.) is observed. The use of Grippferon with the appearance of the very first signs of the disease leads to its interruption. On average, the duration of the disease is reduced by 30-50%.

The use of Grippferon several times reduces the risk of complications: bronchitis, sinusitis, pneumonia, etc. (up to 3.2 times). The use of Grippferon for individual emergency prevention gives a guarantee of protection against the disease up to 96%. It was shown by immunofluorescence that the administration of Grippferon helped to reduce the release of viral antigens found in the nasal passages of patients, already 2 days after the start of treatment. Accordingly, patients cease to be infectious, the chain of infection spreads, which is important for organized groups. This was confirmed when using the drug for prophylactic purposes (during the period of the epidemic in organized groups, the incidence decreased by 2.5-3.5 times). The drug is successfully used for the prevention of nosocomial respiratory viral infections, prevents the occurrence of outbreaks of acute respiratory viral infections in hospitals.

Indications

Prevention and treatment of influenza and SARS in children from birth and adults, including pregnant women.

Contraindications

Individual intolerance to interferon preparations and the components that make up the drug are severe forms of allergic diseases.

Use during pregnancy and lactation

Approved for use during the entire period of pregnancy.

Special instructions

The simultaneous use of intranasal vasoconstrictor drugs is not recommended due to the increased drying effect on the nasal mucosa.

Composition of

1 ml of solution contains recombinant alpha-2 human interferon of at least 10,000 IU.

Dosage and administration of

At the first sign of a disease, instill in the nose for 5 days:

for children under 1 year old - 1 drop in each nasal passage 5 times a day (single dose of 1,000 IU, daily dose of 5,000 IU)

for children from 1 to 3 years old - 2 drops in each nasal passage 3-4 once a day (single dose 2000 ME, daily 6000 - 8000 ME)

for children from 3 to 14 years old - 2 drops in each nasal passage 4-5 times a day (single dose 2000 ME, daily dose 8000-10000 ME)

for adults - 3 drops in each nasal passage 5-6 times a day (single dose of 3,000 ME, daily dose of 15,000 - 18,000 ME).

For the purpose of prevention (SARS and influenza): upon contact with the patient and / or upon hypothermia, the drug is instilled in an age-related dosage 2 times a day for 5-7 days. If necessary, preventive courses are repeated with a seasonal increase in the incidence of the drug, they are instilled at an age-specific dosage in the morning after 1-2 days.

After each instillation, it is recommended to massage your fingers with the wings of the nose for several minutes to evenly distribute the drug in the nasal cavity.

Side effects

Allergic reactions.

Storage conditions

Store at a temperature of 2 to 8 РC in a dry, protected from light and out of reach of children.

Expiration

2 years. After opening the vial - 1 month.

Deystvuyuschee substances

interferon alfa-2b

Dosage form

drops nasal

Firn M, Russia